References
- GPBrowman, DIan Hodson, RJMackenzie, NBestic, LZuraw. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579–89.
- AAForastiere, HGoepfert, MMaor, TFPajak, RWeber, WMorrison, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091–8.
- JPPignon, JBourhis, CDomenge, LDesigné. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on head and Neck Cancer. Lancet 2000;355:949–55.
- JBourhis, ALe Maître, BBaujat, HAudry, JPignon. Individual patients’ data meta-analyses in head and neck cancer. Curr Opin Oncol 2007;19:188–94.
- DJAdelstein, JPSaxton, PLavertu, LTuason, BGWood, JRWanamaker, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 1997;19:567–75.
- TGWendt, GGGrabenbauer, CMRödel, HJThiel, HAydin, RRohloff, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318–24.
- MKoenuma, HKasai, NUchida, TWada, MHattori, TOguma, et al. Pharmacokinetic correlation between experimental and clinical effects on human non-small cell lung cancers of cis-diammineglycolatoplatinum (254-S) and cis-diamminedichloroplatinum. Anticancer Res 1995;15:417–21.
- YKameyama, NOkazaki, MNakagawa, HKoshida, MNakamura, MGemba. Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett 1990;52:15–24.
- MFukuda, TShinkai, KEguchi, YSasaki, TTamura, YOhe, et al. Phase II study of (glycolate-O,O’) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990;26:393–6.
- HAkaza, MTogashi, YNishio, TMiki, TKotake, YMatsumura, et al. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group. Cancer Chemother Pharmacol 1992;31:187–92.
- YInuyama, HMiyake, MHoriuchi, KHayasaki, SKomiyama, KOta. [A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers]. Gan To Kagaku Ryoho 1992;19:871–7; in Japanese.
- NUchida, YTakeda, KHojo, RMaekawa, KSugita, TYoshioka. Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer 1998;34:1796–801.
- TShirasaka, YShimamato, HOhshimo, MYamaguchi, TKato, KYonekura, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548–57.
- HTakemura, SKobayashi, MKatsuno, RAsano, MMorimoto, STachibana, et al. [Clinical phase trial of concurrent chemoradiotherapy combined TS-1 and nedaplatin]. Gan To Kagaku Ryoho 2005;32:2065–9; in Japanese.
- TKodaira, NFuwa, HTachibana, SHidano. Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res 2006;26:2265–8.
- HKato, MFukuchi, RManda, MNakajima, TMiyazaki, MSohda, et al. Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Anticancer Res 2003;23:3493–8.
- FKanzawa, YMatsushima, HNakano, KNakagawa, HTakahashi, YSasaki, et al. Antitumor activity of a new platinum compound (glycolate-o,o’) diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system. Anticancer Res 1988;8:323–7.
- . MFukushima, YShimamoto, TKato, JUchida, RYonekura, HOhshimo, et al.et al.1, an oral combination of tegasfur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 1998;9:817–23.
- KKAng, JHarris, ASGarden, ATrotti, CUJones, LCarrascosa, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 2005;23:3008–15.
- TOhashi, MOhnishi, STanahashi, MMurai. Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer. Jpn J Clin Oncol 2011;41:348–52.